This trial studies treating recurrent/persistent ovarian/endometrial cancer with RAS mutation with selumetinib+olaparib to increase tumor shrinkage & stability compared to selumetinib alone.
- Recurrent Fallopian Tube Cancer
- Recurrent Primary Peritoneal Carcinoma
- Recurrent Ovarian Cancer
- Endometrial Cancer
1 Primary · 4 Secondary · Reporting Duration: Up to 5 years
2 Treatment Groups
Arm II (selumetinib)
1 of 2
Arm I (selumetinib, olaparib)
1 of 2
165 Total Participants · 2 Treatment Groups
Primary Treatment: Arm I (selumetinib, olaparib) · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · Female Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many subjects are engaged in this experiment?
"Affirmative. Clinicaltrials.gov reveals that this medical trial, first posted on March 6th 2023, is actively accepting participants. A total of 165 subjects will be recruited from a single site." - Anonymous Online Contributor
Are there still vacancies for participants in this clinical research?
"Indeed, clinicaltrials.gov confirms that this medical study is currently accepting enrollees. It was initially published on March 6th 2023 and has been recently revised as of March 8th 2023. This trial seeks to enroll 165 patients from a single site." - Anonymous Online Contributor
Has the combination of selumetinib and olaparib received governmental sanction by the FDA?
"Our team at Power assigned Arm I (selumetinib, olaparib) a safety rating of 2 on the 1 to 3 scale. This reflects that selumetinib and olaparib have been proven safe in clinical trials but not yet effective for patients." - Anonymous Online Contributor